As semaglutide-based weight loss treatments such as Ozempic and Wegovy become more popular, new side effects are emerging – ...

The number of Americans taking cutting-edge weight-loss drugs like Ozempic, Wegovy and Zepbound has skyrocketed in recent ...

Ask a Doctor is new series of physician-authored columns offering insights and advice on common health topics. It is not a ...

Ozempic and alcohol-use disorder were central to a recent study that showed the weight-loss drug helped decrease bingeing. Is ...

A healthcare professional reviews your visit and schedules a consultation to determine whether Ozempic, or another GLP-1 medication, is appropriate. If you and the healthcare professional decide ...

Recent research found that people taking semaglutide—the active ingredient in Ozempic and Wegovy—had ... tips to combat hair loss while taking GLP-1s, such as front-loading meals with protein ...

As the popularity of Ozempic, Victoza, Wegovy and other GLP-1 agonists have continued to increase, ... More so have restrictions on insurance coverage for many of them. (Photo by: Michael Siluk ...

Along with Wegovy, Ozempic is known generically as semaglutide, or a synthetic version of a human hormone called glucagon-like peptide one (GLP-1). Some people have used Ozempic for its off-label ...

Ozempic is a glucagon-like peptide-1 (GLP-1) receptor agonist. GLP-1 is a hormone that plays a vital role in glucose metabolism by: Stimulating insulin secretion when blood sugar levels are high ...

Ozempic is a brand-name medication containing the active ingredient semaglutide. It belongs to the class of drugs called glucagon-like peptide-1 receptor agonists (GLP-1 agonists). It mimics the ...

You'd never guess it, but this is the latest exercise craze in action: Call it the Ozempic workout. GLP-1 drugs such as Wegovy, Ozempic, Zepbound and Mounjaro have helped millions of people ...

which is injected like Ozempic and approved for obesity, had no increased risk for NAION compared with those who received non–GLP-1 medications. A small study published last year and a separate ...